Antiplatelet therapy
Antiplatelet therapy has been studied in 25 papers since 2016: 1 trial and 13 observational studies in people, 10 reviews; 15 in the past year. The newest paper, Nov 2, 2026: “Adverse Clinical Events in Secondary Stroke Prevention: A Nationwide Cohort Study in Sweden”.
25 papers study it10 findingsUpdated
6 new papers in 30 daysSee all 25 papers on antiplatelet therapy
At a glance
The findings reach people, from one lab or study. 5 independent labs in 5 countries.
“The largest absolute differences in mortality were associated with taking antiplatelet agents (-14.0%, 95% CrI: -31.4, 1.4%)”
2 of its findings point the other way.
- 5 independent labs in 5 countries
- 2 findings against
- Funders: European Research Council and 7 more
- 1 of 8 findings with company ties
- Human trial1
- Humans13
What did studies of antiplatelet therapy find?
5Studies of antiplatelet therapy measured 5 outcomes, among them mortality, aneurysm growth and thrombosis.
Mortality
no changein humans1
1 study
Mortality
no changein humans1
Antiplatelet therapy was not clearly linked with mortality in humans (Patients with abdominal aortic aneurysms; adjusted analysis).
“but was also not associated with decreased mortality, thrombosis, or aneurysm growth.”
HumansPatients with abdominal aortic aneurysms; adjusted analysisMean follow-up of 1.8 years73% malesn = 886
Annals of vascular surgery
Aneurysm growth
no changein humans1
1 study
Aneurysm growth
no changein humans1
Antiplatelet therapy was not clearly linked with aneurysm growth in humans (Patients with abdominal aortic aneurysms).
“but was also not associated with decreased mortality, thrombosis, or aneurysm growth.”
HumansPatients with abdominal aortic aneurysmsAbdominal aortaMean follow-up of 1.8 years73% malesn = 886
Annals of vascular surgery
Thrombosis
no changein humans1
1 study
Thrombosis
no changein humans1
Antiplatelet therapy was not clearly linked with thrombosis in humans (Patients with abdominal aortic aneurysms).
“but was also not associated with decreased mortality, thrombosis, or aneurysm growth.”
HumansPatients with abdominal aortic aneurysmsMean follow-up of 1.8 years73% malesn = 886
Annals of vascular surgery
Bleeding
no changein humans1
1 study
Bleeding
no changein humans1
Antiplatelet therapy was not clearly linked with bleeding in humans (Patients with abdominal aortic aneurysms).
“antiplatelet therapy was not observed to be associated with an increase in bleeding risk”
HumansPatients with abdominal aortic aneurysmsMean follow-up of 1.8 years73% malesn = 886
Annals of vascular surgery
Dementia
no changein humans1OR 0.94
1 study
Dementia
no changein humans1OR 0.94
Antiplatelet therapy showed no clear effect on dementia in humans (OR 0.94 [95% CI, 0.88-1.00]).
“Antiplatelet therapy was not significantly associated with a reduced risk of cognitive impairment or dementia”
Reviewmean trial follow-up of 5.8 yearsn = 109,860
Age and ageing
What is antiplatelet therapy linked with?
4Studies link antiplatelet therapy with 4 measures, among them mortality, cerebral hemorrhage and dementia.
Mortality
downin humans2OR 0.8
2 studies
Mortality
downin humans2OR 0.8
Antiplatelet therapy is associated with mortality in humans (Chronic coronary disease) (Absolute difference -14.0 percentage points; 95% CrI -31.4 to 1.4).
“The largest absolute differences in mortality were associated with taking antiplatelet agents (-14.0%, 95% CrI: -31.4, 1.4%)”
HumansChronic coronary disease9 years
Guideline-Directed Medical Therapy and Long-Term Outcomes in ISCHEMIA-EXTEND
AHA Scientific Sessions 2026 abstract
Antiplatelet therapy is linked with a lower risk of mortality in secondary multivariable analysis of nursing home residents with COVID-19 (OR 0.80, 95% CI 0.64-0.99).
“current use of antiplatelet therapy (OR 0.80; 95% CI: 0.64-0.99) were both associated with decreased mortality.”
Humansin secondary multivariable analysis of nursing home residents with COVID-19
Age and ageing
Cerebral hemorrhage
upin humans1
1 study
Cerebral hemorrhage
upin humans1
Antiplatelet therapy raises the risk of cerebral hemorrhage in humans.
“Antiplatelet therapy may increase the risk of cerebral hemorrhage”
Review
Brain Dock Guidelines and the Treatment of Asymptomatic Lesions: Criteria and Approaches
Brain and nerve = Shinkei kenkyu no shinpo
Dementia
downin humans1
1 study
Dementia
downin humans1
Antiplatelet therapy is linked with a lower risk of dementia in newly diagnosed CSVD patients without dementia (aOR 0.15, 95% CI 0.05-0.45, p = 0.001).
“The APT was associated with the lower overall dementia risk and the matched OR was statistically significant (aOR 0.15, 95% CI 0.05-0.45, p = 0.001)”
Humansin newly diagnosed CSVD patients without dementian = 262
Frontiers in aging neuroscience
Bleeding
upin humans1
1 study
Bleeding
upin humans1
Antiplatelet therapy raises the risk of bleeding in humans (risk increases with aging).
“the adverse consequences of therapy, such as risk for bleeding increases with aging as well”
Reviewrisk increases with aging
Modulators of platelet function in aging
Platelets